Ross River virus: Molecular and cellular aspects of disease pathogenesis

Nestor E. Rulli, Andreas Suhrbier, Linda Hueston, Mark T. Heise, Daniela Tupanceska, Ali Zaid, Anja Wilmes, Kerry Gilmore, Brett A. Lidbury, Surendran Mahalingam*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

50 Citations (Scopus)


Ross River virus (RRV) is a mosquito-borne alphavirus indigenous to Australia and the Western Pacific region and is responsible for several thousand cases of human RRV disease (RRVD) per annum. The disease primarily involves polyarthritis/arthralgia, with many patients also presenting with rash, myalgia, fever, and/or lethargy. The symptoms can be debilitating at onset, but they usually resolve within 3-6 months. Recent insights into the RRV-host relationship, associated pathology, and molecular biology of infection have generated a number of potential avenues for improved treatment. Although vaccine development has been proposed, the small market size and potential for antibody-dependent enhancement (ADE) of disease make this approach unattractive. Recent insights into the molecular basis of RRV-ADE and the virus's ability to manipulate host inflammatory and immune responses create potential new opportunities for therapeutic invention. Such interventions should overcome virus-induced dysregulation of protective host responses to promote viral clearance and/or ameliorate inflammatory immunopathology.

Original languageEnglish
Pages (from-to)329-342
Number of pages14
JournalPharmacology and Therapeutics
Issue number3
Publication statusPublished - Sept 2005
Externally publishedYes


Dive into the research topics of 'Ross River virus: Molecular and cellular aspects of disease pathogenesis'. Together they form a unique fingerprint.

Cite this